Genervon's GM604 bio-drug receives FDA orphan drug designation for ALS treatment

Genervon Biopharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted an "orphan drug" designation to Genervon's GM604 (a.k.a. GM6) bio-drug for the treatment of Amyotrophic Lateral Sclerosis (ALS). The FDA also granted GM604 a "fast-track" designation for ALS in 2013.

In addition, the U.S. Patent and Trademark Office recently notified Genervon that it will be issued U.S. patent #8673852 on March 18, 2014 for its novel proprietary peptide GM6. GM6 is Genervon's first-in-class, multi-target, master regulator bio-drug that has shown itself to be highly efficacious in a number of therapeutic applications. This brings a total of 53 U.S. and international patents issued to Genervon.

The following lists the clinical trials involving GM6 currently sponsored by Genervon:

ALS Phase 2a Clinical Trial with GM604 (a.k.a. GM6, clinicaltrials.gov NCT01854294)
Genervon finished enrolling ALS patients in January 2014 for its ALS Phase 2a trial under the direction of Dr. Hiroshi Mitsumoto (Columbia University Medical Center in New York) and Drs. Nazem Atassi and Merit Cudkowicz (Massachusetts General Hospital in Boston). Twelve ALS patients, including four in a placebo group, have completed two weeks of dosing.

Parkinson's disease Phase 2a Clinical Trial with GM608 (a.k.a. GM6, clinicaltrials.gov NCT01859381)
Genervon will finish enrolling all six Parkinson's disease (PD) patients this month for its PD Phase 2a trial at Columbia University Medical Center in New York under the direction of Drs. Stanley Fahn and Cheryl Waters.

Ischemic Stroke Phase 2 Clinical Trial with GM602 (a.k.a. GM6, clinicaltrials.gov NCT01221246)
Genervon will finish enrolling ischemic stroke (IS) patients next month for its IS Phase 2 trial at eight sites across the country.

Each of these three Phase 2 trials is a double-blinded, randomized, placebo-controlled trial. GM6 has been safe and well-tolerated in each trial. Genervon expects to present the analysis of the unblinded results of all three trials by the third quarter of 2014.